JP2021522237A5 - - Google Patents

Info

Publication number
JP2021522237A5
JP2021522237A5 JP2020559365A JP2020559365A JP2021522237A5 JP 2021522237 A5 JP2021522237 A5 JP 2021522237A5 JP 2020559365 A JP2020559365 A JP 2020559365A JP 2020559365 A JP2020559365 A JP 2020559365A JP 2021522237 A5 JP2021522237 A5 JP 2021522237A5
Authority
JP
Japan
Prior art keywords
compound according
nitrogen
ring
partially unsaturated
sulfur
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020559365A
Other languages
English (en)
Japanese (ja)
Other versions
JP7479293B2 (ja
JP2021522237A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/028604 external-priority patent/WO2019209757A1/en
Publication of JP2021522237A publication Critical patent/JP2021522237A/ja
Publication of JP2021522237A5 publication Critical patent/JP2021522237A5/ja
Priority to JP2023098522A priority Critical patent/JP2023116712A/ja
Application granted granted Critical
Publication of JP7479293B2 publication Critical patent/JP7479293B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020559365A 2018-04-24 2019-04-23 プテリジノン化合物およびその使用 Active JP7479293B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023098522A JP2023116712A (ja) 2018-04-24 2023-06-15 プテリジノン化合物およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862661744P 2018-04-24 2018-04-24
US62/661,744 2018-04-24
PCT/US2019/028604 WO2019209757A1 (en) 2018-04-24 2019-04-23 Pteridinone compounds and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023098522A Division JP2023116712A (ja) 2018-04-24 2023-06-15 プテリジノン化合物およびその使用

Publications (3)

Publication Number Publication Date
JP2021522237A JP2021522237A (ja) 2021-08-30
JP2021522237A5 true JP2021522237A5 (cg-RX-API-DMAC7.html) 2022-04-22
JP7479293B2 JP7479293B2 (ja) 2024-05-08

Family

ID=66655428

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020559365A Active JP7479293B2 (ja) 2018-04-24 2019-04-23 プテリジノン化合物およびその使用
JP2023098522A Pending JP2023116712A (ja) 2018-04-24 2023-06-15 プテリジノン化合物およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023098522A Pending JP2023116712A (ja) 2018-04-24 2023-06-15 プテリジノン化合物およびその使用

Country Status (11)

Country Link
US (3) US11059826B2 (cg-RX-API-DMAC7.html)
EP (1) EP3784669B1 (cg-RX-API-DMAC7.html)
JP (2) JP7479293B2 (cg-RX-API-DMAC7.html)
CN (1) CN112218865B (cg-RX-API-DMAC7.html)
AR (1) AR114828A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019257651B2 (cg-RX-API-DMAC7.html)
CA (1) CA3097774A1 (cg-RX-API-DMAC7.html)
ES (1) ES2969982T3 (cg-RX-API-DMAC7.html)
IL (1) IL278122B2 (cg-RX-API-DMAC7.html)
TW (1) TWI884914B (cg-RX-API-DMAC7.html)
WO (1) WO2019209757A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3784669B1 (en) 2018-04-24 2023-10-25 Vertex Pharmaceuticals Incorporated Pteridinone compounds and uses thereof
WO2020010451A1 (en) * 2018-07-10 2020-01-16 Trillium Therapeutics Inc. Heteroaromatic-fused imidazolyl amides, compositions and uses thereof as sting agonists
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof
BR112021013924A2 (pt) 2019-01-18 2021-09-21 Astrazeneca Ab Inibidores de pcsk9 e métodos de uso do mesmo
US12617784B2 (en) 2019-01-29 2026-05-05 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. AKT inhibitor
AU2020368368B2 (en) * 2019-10-14 2026-03-19 The Regents Of The University Of California Broad spectrum anti-cancer compounds
WO2022023339A1 (en) 2020-07-29 2022-02-03 Bayer Aktiengesellschaft Aryl substituted pyrrolo-pyridinones and therapeutic uses thereof
EP4238974A4 (en) * 2020-10-28 2024-10-23 Adlai Nortye Biopharma Co., Ltd. HIGH ACTIVITY WNT PATHWAY INHIBITOR COMPOUND
TW202334157A (zh) * 2022-01-29 2023-09-01 大陸商杭州阿諾生物醫藥科技有限公司 一種Wnt通路抑制劑化合物
TW202333697A (zh) * 2022-01-30 2023-09-01 大陸商杭州阿諾生物醫藥科技有限公司 Wnt通路抑制劑化合物
CN114436918B (zh) * 2022-02-23 2023-05-23 郑州大学 环丁-1-烯胺类化合物及其制备方法和在药物中的应用
WO2024022365A1 (zh) * 2022-07-28 2024-02-01 杭州阿诺生物医药科技有限公司 一种Wnt通路抑制剂化合物
US20240217951A1 (en) * 2022-09-23 2024-07-04 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
KR100833371B1 (ko) 2001-04-27 2008-05-28 젠야쿠코교가부시키가이샤 헤테로시클릭 화합물 및 이를 유효 성분으로 하는 항종양제
US6806272B2 (en) * 2001-09-04 2004-10-19 Boehringer Ingelheim Pharma Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
UY27427A1 (es) 2001-09-04 2003-03-31 Boehringer Ingelheim Pharma Nuevas dihidro-pteridinonas, procedimientos para su preparación y su utilización como medicamentos
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
MXPA05001766A (es) 2002-08-14 2005-08-19 Atugen Ag Uso de proteina quinasa n beta.
WO2004089925A1 (en) 2003-04-03 2004-10-21 Semafore Pharmaceuticals, Inc. Pi-3 kinase inhibitor prodrugs
ES2382377T3 (es) 2003-05-30 2012-06-07 Gemin X Pharmaceuticals Canada Inc. Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer
WO2005007623A2 (en) 2003-07-03 2005-01-27 The Trustees Of The University Of Pennsylvania Inhibition of syk kinase expression
LT2612862T (lt) 2004-05-13 2017-01-25 Icos Corporation Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
AU2011226830A1 (en) * 2004-08-14 2011-10-13 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
EP1632493A1 (de) * 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
US7449458B2 (en) 2005-01-19 2008-11-11 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
ES2493466T3 (es) 2005-05-12 2014-09-11 Abbvie Bahamas Ltd. Promotores de la apoptosis
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
WO2007014838A1 (en) * 2005-08-03 2007-02-08 Boehringer Ingelheim International Gmbh Dihydropteridinones in the treatment of respiratory diseases
HRP20140975T1 (hr) 2005-10-07 2014-11-21 Exelixis, Inc. Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova uporaba kao inhibitora fosfatidilinozitol 3-kinaze
WO2007053452A1 (en) 2005-11-01 2007-05-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
HUE028588T2 (hu) 2005-12-13 2016-12-28 Incyte Holdings Corp Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
KR101533461B1 (ko) 2006-04-26 2015-07-02 에프. 호프만-라 로슈 아게 Pi3k저해제로 유용한 티에노[3,2-d]피리미딘 유도체
EP2529621B1 (en) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
HUE029188T2 (en) 2007-03-12 2017-03-28 Ym Biosciences Australia Pty Phenylamino-pyrimidine compounds and their use
US8394794B2 (en) 2007-03-23 2013-03-12 Regents Of The University Of Minnesota Therapeutic compounds
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
MY165582A (en) 2008-03-11 2018-04-05 Incyte Holdings Corp Azetidine and cyclobutane derivatives as jak inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US8865716B2 (en) 2012-02-23 2014-10-21 Boehringer Ingelheim International Gmbh Dihydropteridinones II
EP2958919B1 (en) 2013-02-21 2019-05-22 Boehringer Ingelheim International GmbH Dihydropteridinones i
JP6072308B2 (ja) 2013-02-21 2017-02-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ジヒドロプテリジノンii
KR20160111520A (ko) 2014-01-31 2016-09-26 다나-파버 캔서 인스티튜트 인크. 디히드로프테리디논 유도체 및 그의 용도
WO2015193229A1 (de) 2014-06-19 2015-12-23 Bayer Pharma Aktiengesellschaft Bet-proteininhibitorische 1,4-dihydropyrido[3,4-b]pyrazinone mit meta-substituierter aromatischer amino- oder ethergruppe
CA2986441A1 (en) * 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
CN105801582A (zh) * 2016-04-12 2016-07-27 合肥工业大学 一类新型二氢蝶啶酮类衍生物及其制备方法和在医药上的用途
EP3784669B1 (en) * 2018-04-24 2023-10-25 Vertex Pharmaceuticals Incorporated Pteridinone compounds and uses thereof

Similar Documents

Publication Publication Date Title
JP2019520417A5 (cg-RX-API-DMAC7.html)
CN109415387B (zh) 精氨酸酶抑制剂及其治疗应用
JP2019518768A5 (cg-RX-API-DMAC7.html)
JP2022538228A5 (cg-RX-API-DMAC7.html)
JP2016513130A5 (cg-RX-API-DMAC7.html)
BR112020008836A2 (pt) Moduladores da via de estresse integrada
JP2021515010A5 (cg-RX-API-DMAC7.html)
JP2016509047A5 (cg-RX-API-DMAC7.html)
WO2018013597A4 (en) 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
RU2016126503A (ru) Аналоги кортистатина, их синтез и применения
JP7611154B2 (ja) ピリド-ピリミジニル化合物及び使用の方法
AR073404A1 (es) Anticuerpos anti-receptor il-6, composiciones que los contienen y metodos para producirlos
JP2021522242A5 (cg-RX-API-DMAC7.html)
RU2019141734A (ru) Терапевтические соединения и композиции и способы их применения
JP2019529444A5 (cg-RX-API-DMAC7.html)
RU2014121205A (ru) Производные азолов
EA201592287A1 (ru) Замещенные тетрагидрокарбазольные и карбазолкарбоксамидные соединения
JP7765972B2 (ja) キナゾリニル化合物及び使用方法
RU2013136895A (ru) Новое бициклическое соединение или его соль
JP2017537886A5 (cg-RX-API-DMAC7.html)
RU2013136861A (ru) Новое производное индола или индазола или его соль
JP2022500499A5 (cg-RX-API-DMAC7.html)
MX2021012248A (es) Polimorfos de voruciclib y metodos de elaboracion y uso de los mismos.
JP2022536160A5 (cg-RX-API-DMAC7.html)
RU2007116987A (ru) Новые соединения